FrancophonIA/ELRC3.0 huggingface dataset:
English: The majority of adverse reactions presented in Table 3 were of grade 1 severity in Viekirax and dasabuvircontaining regimens.
Croatian: Većina nuspojava navedenih u Tablici 3 bila je 1. stupnja težine za Viekirax te za kombinacije koje sadrže dasabuvir.
English: NAME OF THE MARKETING AUTHORISATION HOLDER AbbVie Ltd
Croatian: NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET AbbVie Ltd
English: ↑ amiodarone
Croatian: ↑ amiodaron
English: Because of the potential for adverse reactions from the medicinal product in breastfed infants, a decision must be made whether to discontinue breast-feeding or discontinue treatment with Viekirax, taking into account the importance of the therapy to the mother.
Croatian: Budući da lijek može uzrokovati nuspojave u dojenčadi, mora se donijeti odluka hoće li se prekinuti dojenje ili obustaviti liječenje lijekom Viekirax,
English: • quinidine
Croatian: • kinidin
English: Mechanism: Increase in paritaprevir exposures may be due to inhibition of CYP3A/efflu x transporters by lopinavir and higher dose of ritonavir
Croatian: Povećanje izloženosti paritaprevir u moglo bi biti posljedica inhibicije CYP3A/ efluksnih prijenosnika koju uzrokuje lopinavir i viša doza ritonavira.
English: HCV genotype 1b
Croatian: HCV-om genotipa 1b.
English: NA Reduce pravastatin dose by
Croatian: Smanjiti dozu digoksina za
English: No dose adjustment of Viekirax is required in patients with mild hepatic impairment (Child-Pugh A).
Croatian: Nije potrebno prilagođavati dozu lijeka Viekirax u bolesnika s blagim oštećenjem funkcije jetre (Child-Pugh stadij A).
English: Relapse Otherb a. Confirmed HCV ≥ 25 IU/mL after HCV RNA < 25 IU/mL during treatment, confirmed 1 log10 IU/mL
Croatian: Potvrđena razina HCV-a od ≥ 25 IU/ml nakon što je HCV RNK tijekom liječenja bio < 25 IU/ml, potvrđeno povećanje HCV RNK od 1 log10 IU/ml u odnosu na najnižu zabilježenu vrijednosti (nadir) ili postojana razina
English: Treatment with darunavir + Viekirax without dasabuvir is not ombitasvir paritaprevir
Croatian: Liječenje darunavirom u kombinaciji s lijekom Viekirax bez dasabuvira ne ombitasvir paritaprevir dasabuvir
English: SVR12 for HIV-1 co-infected Subjects in TURQUOISE-I
Croatian: SVR12 za ispitanike s istodobnom infekcijom HIV-om tipa 1 u TURQUOISE-I
English: Relapse rates in GT1a cirrhotic subjects by baseline laboratory values are presented in Table 13.
Croatian: Stope relapsa u ispitanika s infekcijom genotipom 1a i cirozom u odnosu na početne laboratorijske vrijednosti prikazane su u Tablici 13.
English: What Viekirax looks like and contents of the pack Viekirax tablets are pink, oblong film-coated tablets of dimmensions 18.8 mm x 10.0 mm, marked with ‘AV1'.
Croatian: Viekirax tablete su ružičaste, duguljaste filmom obložene tablete, dimenzija 18,8 mm x 10,0 mm s oznakom 'AV1'.
English: The safety profile of Viekirax and dasabuvir was similar in subjects without cirrhosis, and with compensated cirrhosis with the exception of increased rates of transient hyperbilirubinemia when ribavirin was part of the regimen.
Croatian: Sigurnosni profil lijeka Viekirax u kombinaciji s dasabuvirom i ribavirinom bio je sličan u bolesnika bez ciroze i u bolesnika s kompenziranom cirozom uz izuzetak povećane učestalosti pojave prolazne hiperbilirubinemije kada je ribavirin bio dio liječenja.
English: A pooled analysis of subjects with genotype 1 HCV infection, who were treated with ombitasvir, paritaprevir, and dasabuvir (a non-nucleotide NS5B inhibitor) with or without ribavirin in the Phase 2b and 3 clinical trials was conducted to explore the association between baseline NS3/4A, NS5A or NS5B substitutions/polymorphisms and treatment outcome in recommended regimens.
Croatian: Učinak supstitucija/polimorfizama HCV-a prisutnih na početku ispitivanja na ishod liječenja Analiza objedinjenih podataka prikupljenih u kliničkim ispitivanjima faze 2b i 3 u ispitanika s infekcijom HCV-om genotipa 1 liječenih ombitasvirom, paritaprevirom i dasabuvirom (nenukleotidni inhibitor NS5B), s ribavirinom (RBV) ili bez njega, provedena je kako bi se istražila povezanost između supstitucija/polimorfizama NS3/4A, NS5A ili NS5B prisutnih na početku ispitivanja i ishoda liječenja preporučenim režimima.
English: • Discontinue treatment in patients who develop evidence of hepatic decompensation.
Croatian: • U bolesnika kod kojih se razviju znakovi dekompenzacije jetre liječenje se mora prekinuti.
English: It contains the active substances ombitasvir, paritaprevir and ritonavir.
Croatian: Viekirax sadrži djelatne tvari ombitasvir, paritaprevir i ritonavir.
English: In all seven trials, the Viekirax dose was 25 mg/150 mg/100 mg once daily and the dasabuvir dose was 250 mg twice daily.
Croatian: U svih je sedam ispitivanja doza lijeka Viekirax iznosila 25 mg/150 mg/100 mg jedanput na dan, a doza dasabuvira 250 mg dvaput na dan.
English: Mechanism: increase in dasabuvir possibly due to CYP2C8 inhibition by trimethoprim
Croatian: povećanje izloženosti dasabuviru kao moguća posljedica inhibicije CYP2C8 trimetoprim om
English: Nifedipine Mechanism: CYP3A4 inhibition
Croatian: Nifedipin Mehanizam: Inhibicija CYP3A4
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 12.5 mg of ombitasvir, 75 mg of paritaprevir and 50 mg of ritonavir.
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Jedna filmom obložena tableta sadrži 12,5 mg ombitasvira, 75 mg paritaprevira i 50 mg ritonavira.
English: Mechanism: decrease possibly due to CYP1A2 induction by ritonavir
Croatian: Mehanizam: smanjenje kao moguća posljedica indukcije CYP1A2 ritonavirom ciklobenzapr in
English: The impact of prior ombitasvir, paritaprevir or dasabuvir treatment experience on the efficacy of other NS5A inhibitors, NS3/4A protease inhibitors, or NS5B inhibitors has not been studied.
Croatian: paritaprevirom ili dasabuvirom na djelotvornost drugih inhibitora NS5A, inhibitora NS3/4A proteaze ili inhibitora NS5B.
English: Mechanism: CYP3A4 induction enzalutamide or mitotane.
Croatian: Mehanizam: CYP3A4 indukcija enzalutamid om ili mitotanom.
English: Expected: ↑ ticagrelor
Croatian: Očekuje se: ↑konivaptan
English: Mechanism: CYP3A4/Pgp inhibition by clarithromyci n and ritonavir.
Croatian: Mehanizam: CYP3A4/Pgp inhibicija klaritromici nom i ritonavirom.
English: België/Belgique/Belgien AbbVie SA
Croatian: België/Belgique/Belgien
English: Viekirax and dasabuvir with RBV Arm A 12 Weeks N = 31
Croatian: Viekirax i dasabuvir s RBV Skupina A 12 tjedana N = 31
English: Increase in dasabuvir exposure is possibly due to CYP2C8 inhibition and increase in paritaprevir possibly due to OATP1B1 inhibition by gemfibrozil.
Croatian: Povećanje izloženosti dasabuviru moglo bi biti posljedica inhibicije CYP2C8, a povećanje izloženosti paritaprevir u moglo bi biti posljedica inhibicije OATP1B1 gemfibrozil paritaprevir/ ritonavir + dasabuvir paritaprevir
English: b. Other includes early drug discontinuation not due to virologic failure missing HCV RNA values in the
Croatian: Ostalo uključuje ranu obustavu liječenja, ali ne zbog virološkog neuspjeha i nedostatak podataka o razinama HCV RNK u razdoblju određivanja SVR12.
English: Viekirax is not recommended in patients with moderate hepatic impairment (Child-Pugh B) (see sections 4.4 and 4.8).
Croatian: Ne preporučuje se primjena lijeka Viekirax u bolesnika s umjerenim oštećenjem funkcije jetre (Child-Pugh stadij B) (vidjeti dijelove 4.4 i 4.8).
English: Interactions between Viekirax with or without dasabuvir and other medicinal products
Croatian: Tablica 2. Interakcije između lijeka Viekirax, s dasabuvirom ili bez njega, i drugih lijekova Lijek/
English: Darunavir combined with Viekirax + dasabuvir is not recommended in patients with extensive PI resistance.
Croatian: Darunavir u kombinaciji s lijekom Viekirax s dasabuvirom ne preporuča se kod bolesnika koji imaju izraženu rezistenciju na inhibitore proteaze.
English: NAME OF THE MEDICINAL PRODUCT Viekirax 12.5 mg/75 mg/50 mg film-coated tablets
Croatian: NAZIV LIJEKA Viekirax 12,5 mg/75 mg/50 mg filmom obložene tablete
English: Viekirax is contraindicated in patients with severe hepatic impairment (Child-Pugh C) (see sections 4.2, 4.3, 4.8 and
Croatian: Viekirax je kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) (vidjeti dijelove 4.2, 4.3, 4.8 i 5.2).
English: Clinical studies in subjects with genotype 1 hepatitis C infection
Croatian: Klinička djelotvornost i sigurnost Klinička ispitivanja u ispitanika s infekcijom virusom hepatitisa C genotipa 1
English: AbbVie Deutschland GmbH & Co. KG Knollstrasse,
Croatian: AbbVie Deutschland GmbH & Co.
English: ANTI-GOUT Colchicine
Croatian: LIJEKOVI PROTIV GIHTA kolhicin
English: Viekirax is contraindicated in patients with severe hepatic impairment (Child-Pugh C) (see sections 4.3 and 5.2).
Croatian: Viekirax je kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) (vidjeti dijelove 4.3 i 5.2).
English: These medicines may be available without a prescription atorvastatin, lovastatin, simvastatin to lower blood cholesterol carbamazepine, phenytoin, phenobarbital for epilepsy cisapride for relieving certain stomach problems clarithromycin, fusidic acid, rifampicin, telithromycin for bacterial infections colchicine in patients who have severe problems with their liver or kidneys for treating gout attacks conivaptan for making the sodium levels in the blood normal efavirenz, etravirine, lopinavir/ritonavir, saquinavir, tipranavir, nevirapine, indinavir, cobicistat for HIV infection enzalutamide for prostate cancer ergotamine, dihydroergotamine for migraine headaches ergonovine, methylergometrine used in childbirth ethinylestradiol-containing medicines such as those contained in most contraceptive pills and vaginal rings used for contraception for contraception itraconozole, ketoconozole, posaconazole, voriconazole for fungal infections midazolam, triazolam (when taken by mouth) for anxiety or trouble sleeping mitotane for symptoms of malignant tumours of the adrenal glands pimozide, lurasidone for schizophrenia quetiapine for schizophrenia, bipolar disorder and major depressive disorder quinidine for abnormal heart rhythms or malaria ranolazine for chronic angina (chest pain)
Croatian: atorvastatin, lovastatin, simvastatin za snižavanje razine kolesterola u krvi karbamazepin, fenitoin, fenobarbital za liječenje epilepsije cisaprid za ublažavanje određenih želučanih tegoba klaritromicin, fusidatna kiselina, rifampicin, telitromicin za liječenje bakterijskih infekcija kolhicin u bolesnika koji imaju teške tegobe s jetrom ili bubrezima za liječenje napadaja gihta konivaptan za reguliranje razine natrija u krvi efavirenz, etravirin, lopinavir/ritonavir, sakvinavir, tipranavir, nevirapin, indinavir, kobicistat za liječenje HIV infekcije enzalutamid za liječenje karcinoma prostate ergotamin, dihidroergotamin za liječenje migrenskih glavobolja ergonovin, metilergometrin lijekovi koji se koriste pri porodu lijekovi koji sadrže etinilestradiol koji se nalazi u većini kontracepcijskih tableta i vaginalnim prstenovima koji se koriste za kontracepciju za kontracepciju itrakonazol, ketokonazol, posakonazol, vorikonazol za liječenje gljivičnih infekcija midazolam, triazolam (kada se uzimaju kroz usta)
English: Purpose of the medicine
Croatian: UPUTA O LIJEKU
English: Mechanism: CYP3A4/OA TP1B inhibition
Croatian: Mehanizam: CYP3A4/ OATP1B inhibicija
English: In TURQUOISE-I, the SVR12 rates in HCV/HIV-1 co-infected subjects were consistent with SVR12 rates in the phase 3 trials of HCV mono-infected subjects.
Croatian: U ispitivanju TURQUOISE-I stopa SVR12 u ispitanika s kroničnom infekcijom hepatitisom C i istodobnom infekcijom HIV-om tipa 1 odgovarala je stopi SVR12 u ispitivanjima faze III u ispitanika s infekcijom samo HCV-om.
English: Vitamin E polyethylene glycol succinate Propylene glycol monolaurate Sorbitan monolaurate Colloidal anhydrous silica (E551) Sodium stearyl fumarate
Croatian: Jezgra tablete: kopovidon vitamin E polietilenglikolsukcinat propilenglikolmonolaurat sorbitanmonolaurat silicijev dioksid, koloidni, bezvodni (E551) natrijev stearilfumarat
English: Viekirax + dasabuvir duloxetine
Croatian: Viekirax bez dasabuvira duloksetin
English: Viekirax and dasabuvir without ribavirin for 12 weeks
Croatian: Viekirax i dasabuvir tijekom 12 tjedana bez ribavirina
English: Effect of dasabuvir on paritaprevir/ritonavir and ombitasvir In the presence of dasabuvir, paritaprevir exposures increased by 50% to 65% while there was no change in ombitasvir exposures.
Croatian: U prisutnosti dasabuvira, izloženost paritapreviru se povećala za 50 do 65%, dok nije bilo promjene u izloženosti ombitasviru.
English: This is due to liver function changes during treatment with Viekirax ± dasabuvir.
Croatian: To je posljedica promjene funkcije jetre prilikom liječenja lijekom Viekirax, s dasabuvirom ili bez njega.
English: Viekirax is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus).
Croatian: Viekirax je antivirusni lijek koji se koristi za liječenje odraslih koji boluju od kroničnog (dugotrajnog)
English: OATP1B1/3 substrates evaluated in drug interaction studies include pravastatin and rosuvastatin (see Table 2).
Croatian: OATP1B1/3 supstrati ocijenjeni u ispitivanjima inaterakcija uključuju pravastatin i rosuvastatin
English: Monitor tacrolimus levels and adjust dose and/or dosing frequency as needed.
Croatian: Pratiti razine takrolimusa te po potrebi prilagoditi dozu i/ili učestalost primjene.
English: Viekirax is not recommended in patients with moderate hepatic impairment (Child-Pugh B).
Croatian: Ne preporučuje se primjena lijeka Viekirax u bolesnika s umjerenim oštećenjem funkcije jetre (ChildPugh stadij B).
English: In patients with renal or hepatic impairment, use of colchicine with Viekirax with or without dasabuvir is contraindicated (see section 4.3 and 4.5).
Croatian: Kod bolesnika s oštećenjem funkcije bubrega ili jetre je kontraindicirana istodobna primjena kolhicina i lijeka Viekirax s dasabuvirom ili bez njega (vidjeti dijelove 4.3 i 4.5).
English: For patients that require ribavirin, refer to the ribavirin Summary of Product Characteristics for information regarding use in patients with renal impairment.
Croatian: U bolesnika u kojih je potrebna primjena ribavirina, za informacije o primjeni kod bolesnika s oštećenjem funkcije bubrega vidjeti Sažetak opisa svojstava lijeka za ribavirin.
English: ↑ fluvastatin ↑ pitavastatin
Croatian: ↑ kvetiapin ↑ lurasidon
English: Mechanism: CYP3A4/Pgp inhibition by erythromycin, paritaprevir, ritonavir and dasabuvir.
Croatian: Mehanizam: CYP3A4/Pgp inhibicija erithromicin om, paritaprevir om, ritonavirom i dasabuviro m.
English: Viekirax 12.5 mg/75 mg/50 mg film-coated tablets ombitasvir/paritaprevir/ritonavir
Croatian: Viekirax 12,5 mg / 75 mg / 50 mg filmom obložene tablete ombitasvir / paritaprevir / ritonavir
English: Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 200 mg, and ritonavir 100 mg, with dasabuvir 400 mg were evaluated in subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment.
Croatian: Farmakokinetika kombinacije ombitasvira u dozi od 25 mg, paritaprevira u dozi od 200 mg i ritonavira u dozi od 100 mg s dasabuvirom u dozi od 400 mg ocijenjena je u ispitanika s blagim (Child-Pugh stadij A), umjerenim (Child-Pugh stadij B) i teškim (Child-Pugh stadij C) oštećenjem funkcije jetre.
English: Mechanism: CYP3A inhibition by ritonavir
Croatian: Mehanizam: CYP3A inhibicija ritonavirom
English: SVR12 for genotype 1-infected peginterferon+ribavirin-experienced subjects in SAPPHIRE-II
Croatian: SVR12 za ispitanike prethodno liječene peginterferonom i ribavirinom s infekcijom genotipom 1 u ispitivanju SAPPHIRE-II
English: ANTIPSYCHOTICS Lurasidone
Croatian: ANTIPSIHOTICI lurasidon pimozid kvetiapin
English: Similar effect expected as observed with Viekirax + dasabuvir.
Croatian: Očekuje se učinak sličan onome primijećenom kod primjene kombinacije Viekirax + dasabuvir.
English: Thirty four subjects (29 with HCV genotype 1a infection and 5 with HCV genotype 1b infection) were enrolled who had not received treatment for HCV infection after transplantation and had a METAVIR fibrosis score of F2 or less.
Croatian: Uključeno je 34 ispitanika (29 s infekcijom HCV-om genotipa 1a i 5 s infekcijom HCV-om genotipa
English: increase in HCV RNA from nadir, or HCV RNA persistently ≥ 25 IU/mL with at least 6 weeks of treatment.
Croatian: HCV RNK od ≥ 25 IU/ml uz najmanje 6 tjedana liječenja.
English: Treatment-naïve pegIFN + RBV experienced Prior relapse Prior partial response Prior null response 100% (32/32) Other pegIFN/RBV failures TOTAL +Other types of pegIFN/RBV failure include less well documented non-response, relapse/breakthrough or other pegIFN failure.
Croatian: UKUPNO +Ostale vrste neuspjeha liječenja kombinacijom pegIFN/RBV uključuje manji precizno dokumentirani izostanak odgovora, relaps/proboj ili druge oblike neuspjeha liječenja kombinacijom pegIFN/RBV.
English: Mechanism: CYP3A4 induction by rifampicin.
Croatian: Mehanizam: CYP3A4 indukcija rifampicino m.
English: Viekirax with or without dasabuvir ethinylestradiol
Croatian: Viekirax s dasabuvirom ili bez njega etinilestradiol
English: If you are not sure, talk to your doctor or pharmacist before taking Viekirax.
Croatian: razgovarajte sa svojim liječnikom ili ljekarnikom prije nego uzmete lijek Viekirax.
English: SVR12 for genotype 1-infected subjects with compensated cirrhosis who were treatmentnaïve or previously treated with pegIFN/RBV
Croatian: Tablica 12. SVR12 za ispitanike s infekcijom genotipom 1 i kompenziranom cirozom koji prethodno nisu bili liječeni ili su primali pegIFN/RBV Ishod liječenja
English: Increase in raltegravir exposures may be due to UGT1A1 inhibition by paritaprevir, ombitasvir.
Croatian: Povećanje izloženosti raltegraviru moglo bi biti posljedica inhibicije UGT1A1 koju uzrokuju paritaprevir, ombitasvir i dasabuvir.
English: SVR12 for genotype 4-infected, subjects who were treatment-naïve or previously treated with pegIFN/RBV in PEARL I
Croatian: Tablica 17. Stope SVR12 za ispitanike s infekcijom genotipom 4, prethodno neliječene ili prethodno liječene pegIFN/RBV-om u ispitivanju PEARL I
English: GT1b Arm A: Viekirax and dasabuvir + RBV Arm B: Viekirax and dasabuvir Treatment-naïve and peginterferon+ribavirin -experienced, with compensated cirrhosis
Croatian: GT1a skupina A: Viekirax i dasabuvir + RBV skupina B: Viekirax i dasabuvir Ispitanici prethodno liječeni peginterferonom i ribavirinom, bez ciroze SAPPHIRE II
English: CONTRACEPTIVES Ethinylestradiol/ norgestimate
Croatian: KONTRACEPTIVI etinilestradiol/ norgestimat mg jedanput na dan
English: Increase in paritaprevir exposures may be due to inhibition of OATP1B1/B3 and CYP3A by atazanavir.
Croatian: Povećanje izloženosti paritaprevir u moglo bi biti posljedica inhibicije OATP1B1/ B3 i
English: Mechanism: CYP2C19 induction by ritonavir.
Croatian: Mehanizam: CYP2C19 indukcija ritonavirom.
English: Mechanism: CYP2C19 induction by ritonavir
Croatian: Mehanizam: CYP2C19 indukcija ritonavirom
English: Resistance to paritaprevir and ombitasvir conferred by variants in NS3 and NS5A respectively, selected in cell culture or identified in Phase 2b and 3 clinical trials were phenotypically characterised in the appropriate genotype 1a or 1b replicons.
Croatian: NS3 ili NS5A izdvojenima u staničnoj kulturi ili identificiranima u kliničkim ispitivanjima faze 2b i 3,
English: Mechanism: Intestinal Pgp inhibition by paritaprevir and ritonavir.
Croatian: Mehanizam: inhibicija crijevnog Pgp paritaprevir om i ritonavirom.
English: Clinical monitoring and dose reduction is recommended for angiotensin receptor blockers when coadministered with Viekirax with or without dasabuvir.
Croatian: Preporučuje se kliničko praćenje i smanjenje doze za blokatore angiotenzinskih receptora kada se primjenjuju istodobno s lijekom
English: ANTIHISTAMINES Astemizole
Croatian: ANTIHISTAMINICI astemizol terfenadin
English: Mechanism: CYP3A4/Pgp inhibition by conivaptan and paritaprevir/ ritonavir/ombi tasvir
Croatian: Mehanizam: CYP3A4/Pgp inhibicija konivaptano m i paritaprevir om/ritonavir om/ombitas virom
English: S-warfarin paritaprevir ombitasvir
Croatian: S-varfarin paritaprevir ombitasvir dabigatran eteksilat
English: Viekirax and dasabuvir without ribavirin or with weight-based ribavirin for 12 weeks Treated subjects (N=419) had a median age of 50 years (range: 19 to 70), 45.8% were male; 4.8% were Black; 9.3% had a history of depression or bipolar disorder; 73.3% had baseline HCV RNA of at least 800,000 IU/mL; 20.3% had portal fibrosis (F2) and 10.0% had bridging fibrosis (F3).
Croatian: Viekirax i dasabuvir tijekom 12 tjedana bez ribavirina ili s ribavirinom čija je doza temeljena na težini Medijan dobi liječenih ispitanika (N=419) iznosio je 50 godina (raspon: 19 do 70); 45,8% bili su muškarci; 4,8% bili su crnci;; 9,3% imalo je depresiju ili bipolarni poremećaj u anamnezi; 73,3%
English: For patients coadministered ribavirin refer to the Summary of Product Characteristics of ribavirin.
Croatian: Za bolesnice koje istodobno primaju ribavirin, pročitajte i Sažetak opisa svojstava lijeka za ribavirin.
English: Mechanism: CYP3A4 inhibition by ritonavir and UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Croatian: Mehanizam: inhibicija CYP3A4 ritonavirom te inhibicija UGT-a koju uzrokuju paritaprevir, ombitasvir i dasabuvir.
English: Outcome for subjects without SVR12 On-treatment virologic failure Post-treatment relapse Other
Croatian: Virološki neuspjeh tijekom liječenja Relaps nakon liječenja
English: Ethinylestradiol-containing oral contraceptives are contraindicated (see section 4.3).
Croatian: Oralni kontraceptivi koji sadrže etinilestradiol su kontraindicirani (vidjeti dio
English: Viekirax and dasabuvir with investigator chosen ribavirin dose for 24 weeks
Croatian: Viekirax i dasabuvir tijekom 24 tjedna s ribavirinom čiju je dozu odredio ispitivač
English: Mechanism: UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Croatian: Mehanizam: UGT1A1 inhibicija paritaprevir om, ombitasviro m i dasabuviro m.
English: Viekirax safety and efficacy have been established in combination with dasabuvir and/or ribavirin.
Croatian: Istodobna primjena s drugim antiviroticima koji djeluju izravno na HCV Ustanovljene su sigurnost i djelotvornost lijeka Viekirax u kombinaciji s dasabuvirom i/ili ribavirinom.
English: CYP3A4 inhibition by ritonavir and increase in paritaprevir exposures may be due to OATP/BCRP/ P-gp inhibition by ciclosporin.
Croatian: Učinak na ciklosporin posljedica je inhibicije CYP3A4 ritonavirom, dok bi povećanje izloženosti paritaprevir u moglo biti posljedica inhibicije OATPa/BCRP
English: Decrease digoxin dose by 30-50%.
Croatian: NP Dozu pravastatina treba smanjiti za 50%.
English: SVR12 for genotype 1b-infected peginterferon+ribavirin-experienced subjects in PEARL II
Croatian: Tablica 11. SVR12 za ispitanike prethodno liječene peginterferonom i ribavirinom s infekcijom genotipom 1b u ispitivanju PEARL II
English: ↔ es citalopram
Croatian: Sdezmetilcitalopram
English: Posology
Croatian: buprenorfin